Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-NY ESO-1 mTCR PBL in metastatic cancer
NCT01967823Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2013
- Primary completion
- Apr 2020
- Countries
- 1
01
Overview
A Phase 2 trial of Anti-NY ESO-1 mTCR PBL in melanoma, meningioma, breast cancer, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Started Oct 2013; status: completed.
02
Drugs
Anti-NY ESO-1 mTCR PBL
03
Conditions
melanomameningiomabreast cancernon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01967823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01967823.